Zolgensma Stands Out In Strong Q4 For Novartis
Big Sales Rises For Cosentyx And Entresto
CEO Vas Narasimhan is confident the Swiss major's gene therapy for spinal muscular atrophy will outperform present and future rivals – Biogen's Spinraza and Roche's risdiplam, respectively – as "we have a better profile simply because we are a one-time therapy."
